 Home > Active Ingredient News > Antitumor Therapy > Hepatology: Adjuvant radiotherapy can effectively consolidate the curative effect of narrow margin hepatectomy for liver cancer

Hepatology: Adjuvant radiotherapy can effectively consolidate the curative effect of narrow margin hepatectomy for liver cancer

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

checkers 2 5

makeup cancer patients

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Surgical resection is the main treatment for hepatocellular carcinoma (HCC); however, some patients with liver cancer who undergo surgery still have a high recurrence rate and mortality rate
.

This study aimed to study the efficacy and safety of postoperative intensity-modulated radiotherapy (IMRT) for HCC after narrow margin hepatectomy

This is a single-arm, prospective phase II study that assessed the overall survival (OS), disease-free survival (DFS), recurrence, and toxicity of HCC patients receiving adjuvant radiotherapy
.

The inclusion criteria include: pathological diagnosis of HCC after hepatectomy, narrow pathological margin (the distance between the cancer tissue is <1cm), the age of 18 years, and the ECOG performance status score of 0 or 1

OS and DFS

From 2008 to 2016, a total of 76 patients with narrow margins were recruited
.

The median follow-up was 70 months; the 3-year OS and PFS rates were 88.

Recurrence rate

The most common grade 3 toxicities associated with radiotherapy are leukopenia (7.
9%), elevated alanine aminotransferase (3.
9%) and aspartate aminotransferase (2.
6%), and thrombocytopenia (1.
3%) )
.

No typical or atypical radiation-induced liver disease was found

In summary, adjuvant radiotherapy is an effective, well-tolerated and promising adjuvant treatment plan, suitable for HCC patients undergoing narrow margin hepatectomy
.

The results of this study support the continuation of related phase III trials

Adjuvant radiotherapy is an effective, well-tolerated and promising adjuvant treatment plan.

Original source:

Chen Bo,Wu Jian-Xiong,Cheng Shu-Hui et al.

Phase II study of adjuvant radiotherapy following narrow -margin hepatectomy in patients with hepatocellular carcinoma in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.